EPOCH-F

EPOCH-F is a combination chemotherapy regimen developed as a salvage therapy for multiple myeloma, particularly in patients being considered for reduced-intensity allogeneic hematopoietic stem cell transplantation (RI-alloHSCT). The regimen consists of six drugs administered in specific sequences and dosages: - Etoposide (a topoisomerase II inhibitor) - Prednisone (a glucocorticoid steroid) - Vincristine (Oncovin; a vinca alkaloid that inhibits microtubule formation) - Cyclophosphamide (an alkylating agent) - Doxorubicin (Adriamycin; an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II) - Fludarabine (a purine analog antimetabolite) The primary goals of the EPOCH-F regimen are to achieve tumor control and deplete host lymphocytes, thereby facilitating donor engraftment prior to RI-alloHSCT. In clinical studies, this regimen has demonstrated manageable toxicity profiles—primarily hematologic—and effective disease control with consistent full donor engraftment in multiple myeloma patients[1].